Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.43 |
| ▸ | AR | P10275 | 5/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26444396 | 0.82 | EPHX2 (0.44) | EPHX2ARPGRCYP11B1CYP11B2 | |
| SCHEMBL4628852 | 0.81 | EPHX2 (0.46) | EPHX2ARPGRCYP11B1CYP11B2 | |
| SCHEMBL12422332 | 0.78 | CA12 (0.56) | EPHX2ARPGRCA12CA1 | |
| SCHEMBL756255 | 0.78 | PTPN7 (0.50) | EPHX2ARPGRCYP11B1CYP11B2 | |
| SCHEMBL29775423 | 0.78 | PTPN7 (0.50) | EPHX2ARPGRCYP11B1CYP11B2 | |
| SCHEMBL29775318 | 0.78 | CA12 (0.56) | EPHX2ARPGRCA12CA1 | |
| SCHEMBL2900162 | 0.78 | EPHX2 (0.44) | EPHX2ARPGRCYP11B1CYP11B2 | |
| SCHEMBL13066064 | 0.77 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL77088 | 0.76 | FFAR4 (0.56) | EPHX2ARPGRCYP11B1CYP11B2 | |
| SCHEMBL755578 | 0.76 | ALDH1A1 (0.53) | EPHX2ARPGRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | EPHX2 3129/4885AR 4143/4885PGR 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.